Boston Scientific Corporation $BSX Stake Increased by Pinnacle Wealth Planning Services Inc.

Pinnacle Wealth Planning Services Inc. boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 35.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,743 shares of the medical equipment provider’s stock after acquiring an additional 2,307 shares during the period. Pinnacle Wealth Planning Services Inc.’s holdings in Boston Scientific were worth $939,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. Kingsview Wealth Management LLC increased its holdings in Boston Scientific by 2.6% in the first quarter. Kingsview Wealth Management LLC now owns 6,735 shares of the medical equipment provider’s stock valued at $679,000 after buying an additional 172 shares during the last quarter. Private Advisor Group LLC increased its holdings in Boston Scientific by 10.8% in the first quarter. Private Advisor Group LLC now owns 38,274 shares of the medical equipment provider’s stock valued at $3,861,000 after buying an additional 3,734 shares during the last quarter. Formidable Asset Management LLC acquired a new stake in Boston Scientific during the first quarter valued at approximately $206,000. Finally, Kestra Private Wealth Services LLC lifted its holdings in Boston Scientific by 21.0% during the 1st quarter. Kestra Private Wealth Services LLC now owns 40,130 shares of the medical equipment provider’s stock worth $4,048,000 after buying an additional 6,977 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

BSX stock opened at $101.71 on Tuesday. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The stock has a market capitalization of $150.78 billion, a price-to-earnings ratio of 54.39, a PEG ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock’s fifty day moving average is $99.59 and its two-hundred day moving average is $102.55.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the prior year, the firm earned $0.63 earnings per share. The company’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity

In related news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 175,782 shares of company stock valued at $17,742,314. 0.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BSX. Wells Fargo & Company boosted their price target on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Morgan Stanley lifted their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Barclays boosted their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Robert W. Baird raised their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Finally, Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Boston Scientific has an average rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.